Effect of Razi Pills on the Treatment of Chronic Low Back Pain

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180227038884N1

Enrollment

Registered

2018-04-20

Start date

2016-09-22

Completion date

Unknown

Last updated

2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic low back pain. Loin pain. Low back strain .Lumbago

Interventions

Intervention 1: Intervention group.The intervention group consisted of 26 people. For all people in the intervention group, the Razi tablet manufactured by Niac Pharmaceuticals Company was given as fo

Eligibility

Sex/Gender

All

Age

19 Years to 59 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria included patients aged 19 to 59 years with chronic LBP complaints.

Exclusion criteria

Exclusion criteria: , no surgical indication and no history of trauma, suspected malignancy, steroid use, and chronic infection, non-pregnant and non-lactating women

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: At the beginning of the study. Fourth and eighth weeks. Method of measurement: VAS and Roland-Maurice questionnaires.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactValiollah Gerayeli Malek

Tehran University of Medical Sciences

v-gerayelimalek@razi.tums.ac.ir+98 21 8877 3521

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026